Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
← catalyst calendarSponsored by Adaptive Biotechnologies (industry) · ADPT — their whole pipeline →. With Stanford University.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
300estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-01 | actual | When the study began enrolling |
| Primary completion | 2025-09-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-08-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Follicular Lymphoma
- Diffuse Large B Cell Lymphoma
- Mantle Cell Lymphoma
Intervention
- Device: ClonoSEQ
Primary outcome
what the primary-completion date above is the date OFPrimary Outcome: Predicting Progression Free Survival
measured 0-18 months
Permalink · ADPT's whole pipeline · Catalyst calendar · Every registered study · What changed